To characterize the immune state and in vivo response of CTCL patients receiving immunotherapy, we assembled a cohort of 39 late-stage MF or SS patients enrolled in either CITN-10,5 testing the efficacy of anti-PD-1 (Pembrolizumab) monotherapy, or CITN-13, testing the efficacy of IFN-γ and anti-PD-1 (Pembrolizumab) combination therapy (Table S1). This evidence concerns the gene IFNG and mycosis fungoides.